A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Sabbioni, Safah, Sanford, Sartor, Scandurro, Scher, Seth, Shan, Shellito, Shuh, Sikka, Srivastav, Sturtevant, D. Sullivan, K. Sullivan, Sun
Gabriele SabbioniGabriele Sabbioni, Ph.D.

Associate Professor of Environmental Health Sciences
sabbioni@tulane.edu
(504) 988-2771, (504) 988-1726 fax
1440 Canal St., Ste. 2100, New Orleans, LA 70112-2699

 

 

 

Biographical information:
After studying chemistry (Master's, PhD) in Berne, Switzerland, Professor Sabbioni performed his first postdoctoral work in the field of bioorganic chemistry at the University of Toronto (1982). He worked in toxicology at the Division of Toxicology of the Massachusetts Institute of Technology (MIT) in 1984. In 1986, he had the opportunity to teach as a visiting assistant professor at the Department of Chemistry of the Lewis and Clark College in Portland, Oregon. One year later, he started work as an independent researcher at the Institute of Pharmacology and Toxicology of the University of Wurzburg (Germany). At the end of 1992, he obtained his postdoctoral lecturing qualification (Habilitation) from the University of Wurzburg. The title of his postdoctoral thesis (Habilitationsschrift) was "Biomonitoring of aromatic amines and aflatoxins." In 1996, he obtained a position as a non-tenure-track associate professor of pharmacology and toxicology at the University of Munich. During the last 22 years, his research has focused on the development of methods (protein and DNA adducts) for biomonitoring of people exposed to carcinogens. He has also been teaching courses in toxicology and pharmacology and supervising undergraduate and PhD students and postdoctoral fellows.

Recent Publications:

  • Sabbioni G, Sepai O, Hirvonen A, Norppa H, Jarventaus H, Yan H, Brooks LR, Warren SH, DeMarini DM, Liu YY. Comparison of biomarkers in workers exposed to 2, 4, 6-trinitrotoluene. Biomarkers, 12:21-37, 2007.
  • Beyerbach A, Rothman N, Bhatnagar VK, Kashyap R, Sabbioni G. Hemoglobin adducts in workers exposed to benzidine and azo dyes. Carcinogenesis, 27:1600, 2006.
  • Sabbioni G, Jones CR, Sepai O, Hirvonen A, Norppa H, Jarventaus H, Glatt HR, Pomplun D, Yan H, Brooks LR, Warren SH, DeMarini DM, Liu YY. Biomarkers of exposure, effect and susceptibility in workers exposed to nitrotoluenes. Cancer Epidemiol Biomarkers & Prev, 15:559, 2006.
  • Jones CR, Liu YY, Sepai O, Yan H, Sabbioni G. Internal exposure, health effects and cancer risk of humans exposed to chloronitrobenzene. Environ Science & Technol, 40:387, 2006.
  • Sabbioni G, Liu YY, Yan H, Sepai O. Hemoglobin adducts, urinary metabolites, and health effects in 2, 4, 6-trinitrotoluene exposed workers. Carcinogenesis, 26: 1272, 2005.
  • Jones CR, Liu YY, Sepai O, Yan H, Sabbioni G. Hemoglobin adducts in workers exposed to nitrotoluenes. Carcinogenesis, 26: 133, 2005.
  • Jones CR, Beyerbach A, Seffner W, Sabbioni G. Hemoglobin and DNA adducts in rats exposed to 2-nitrotoluene. Carcinogenesis, 24: 779, 2003.
  • Sabbioni G, Jones CR. Biomonitoring of arylamines and nitroarenes. Biomarkers, 7: 347, 2002.
  • Bolognesi C, Baur X, Marzcynski B, Norppa H, Sepai O, Sabbioni G. Carcinogenic risk of toluene diisocyanate and 4, 4'-methylenediphenyl diisocyanate: epidemiological and experimental evidence. Crit Rev Toxicol, 31: 737, 2001.
  • Sabbioni G, Sepai O. Determination of human exposure to mycotoxins. In: Sinha KK, Bhatnagar D (eds) Mycotoxins in Agriculture and Food Safety. Marcel Dekker, New York, pp. 183-226.

Back to the top

Hana Safah Hana Safah, M.D.

Associate Professor of Medicine
Director, Hematology / Medical Oncology Fellowship Program
Medical Director, Bone Marrow Transplant Program
Medical Director, Institutional Review Board
TCC Associate Member
hsafah@tulane.edu
(504) 599-6565, (504) 988-6077 fax
1430 Tulane Ave., Box SL-68, New Orleans, LA 70112-2699


Specialties, publications, and research:

  • Lymphoma, leukemia, bone marrow transplant, clinical research
  • "Chronic myelogenous leukemia protocol" (Schering)
  • "Efficacy and safety of PEG-rHuMGDF in patients with delayed platelet engraftment" (Amgen)
  • Safah H, Weiner RS
    "The role of bone marrow transplantation in the management of advanced local disease"

Back to the top

Robert Sanford Robert Sanford, Ph.D.

Radiation Oncologist
Assistant Professor of Radiology
TCC Associate Member
rsanford@tulane.edu
(504) 988-6314, (504) 988-6362 fax
1415 Tulane Ave., Box HC-62, New Orleans, LA 70112


Biographical information:

Dr. Sanford received his B.S. in Mechanical Engineering in 1984 from Tulane University with one year of study at the University of Sheffield, England. He received his Masters and Ph.D. degrees in Particle Physics in 1999 from Louisiana State University. Dr. Sanford began a medical physics residency in 1999 under Dr. M.S. Al-Ghazi at the University of California, Irvine and was bestowed a Young Physicist Award by the American College of Medical Physics in 2000. Dr. Sanford continued at UCI as a clinical instructor and joined the Tulane faculty in February 2002. Dr. Sanford's primary clinical duties include the calibration, quality assurance, acceptance testing, and commissioning of all radiation therapy equipment, radioactive treatment sources, computerized treatment planning systems, and radiation measuring devices housed in the Department of Radiation Oncology. Clinical responsibilities also include overseeing the determination of radiation dose distributions in patients undergoing treatment and tracking doses delivered to patients. Research interests include intensity modulated radiation therapy (IMRT) and Monte Carlo treatment planning.


Recent Publications:
  • Sanford R. (1999) Observation of the east-west anisotrophy of the atmospheric neutrino flux. Phys Rev Lett 82: 5194-5197.
  • Sanford R. (1999) Measurement of the solar neutrino energy spectrum using neutrino-electron scattering. Phys Rev Lett 82: 2430-2434.
  • Sanford R. (1999) Constraints on neutrino oscillation parameters from the day-night soalr neutrino fluxes at Super-Kamiokande. Phys Rev Lett 82: 1810-1814.
  • Sanford R. (2000) Tan neutrinos favored over sterile neutrinos in atmospheric muon neutrinos in atmospheric muon neutrino oscillations. Phys Rev Lett 83: 3999-4003.

Back to the top

Oliver SartorOliver Sartor, M.D.

The Gerald & Flora Jo Mansfield Piltz Endowed Professor in Cancer Research
Professor, Department of Medicine: Section of Hematology & Medical Oncology and Department of Urology
TCC Program Member
osartor@tulane.edu
(504) 988-7869, (504) 988-5059 fax
1430 Tulane Ave., SL-42, New Orleans, LA 70112


Biographical information:

Dr. Oliver Sartor is the Piltz Professor of Cancer Research in the Departments of Medicine and Urology at Tulane University School of Medicine. He is a medical oncologist with an interest in prostate cancer from both a basic and clinical perspective. He is on the Department of Defense Integration Panel for prostate cancer research and is the chairman-elect of the organization as well as co-editor-in-chief of the peer-reviewed journal Clinical Genitourinary Cancer. He is also the current medical oncology chair of the Radiation Oncology Treatment Group Genitourinary Cancer Committee. In addition, Dr. Sartor is a SPORE project co-PI at Dana-Farber Cancer Center on a translational project involving the clinical outcomes and consequences of the 8q24 risk alleles. Dr. Sartor's current research interests include clinical trials in advanced prostate cancer with novel agents and novel combinations of agents. His collaborative projects include novel concepts in prostate stem cells and germ line assessment of prostate cancer risk.

Recent Publications:

  • Zabaleta J, Lin HY, Sierra RA, Hall MC, Clark PE, Sartor O, Hu JJ, Ochoa AC. Interactions of cytokine gene polymorphisms in prostate cancer risk. Carcinogenesis, Jan. 3, 2008 [epub ahead of print].
  • Nakabayashi M, Sartor O, Jacobus S, Regan MM, McKearn D, Ross RW, Kantoff PW, Taplin ME, Oh WK. Response to docetaxel/carboplatin-based chemotherapy as first- and second-line therapy in patients with metastatic hormone-refractory prostate cancer. BJU Int, 101:308-312, 2008.
  • Wu D, Zhau DE, Huang WC, Igbal S, Habib FK, Sartor O, Cvitanovic, L, Marshall FF, Xu Z, Chung LW. cAMP-responsive element-binding protein regulates vascular endothelial growth factor expression: implication in human prostate cancer bone metastasis. Oncogene, 26:5070-7, 2007.
  • Sartor O, Reid RH, Bushnell DL, Quick DP, Ell PJ. Safety and efficacy of repeat administration of samarium SM-153 lexidronam to patients with metastatic bone pain. Cancer, 109:637-43, 2007.
  • Eggener SE, Scardino PT, Carroll PR, Zelefsky MJ, Sartor O, Hricak H, Wheeler TM, Fine SW, Trachtenberg J, Rubin MA, Ohori M, Kuroiwa K, Rossignol M, Abenhaim L. International Task Force on Prostate Cancer and the Focal Lesion Paradigm. Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities. J Urol, 178: 2260-7, 2007.
  • Crawford ED, Sartor O, Chu F, Perez R, Karlin G, Garrett JS. A 12- month clinical study of LA-2585 (45.0 mg): a new 6-month subcutaneous delivery system for leuprolide acetate for the treatment of prostate cancer. J Urol, 175(2): 533-6, 2006.
  • Sartor O, Loriaux L. The emotional burden of low-risk prostate cancer: proposal for a change in nomenclature. Clin Genitourinary Cancer, 5(1) 16-7, 2006.
  • Koochekpour S, Zhuang YJ, Beroukhim R, Hsieh CL, Hofer MD, Zhau HE, Hiraiwa M, Pattan DY, Ware JL, Luftig RB, Sandhoff K, Sawyers CL, Pienta KJ, Rubin MA, Vessella RL, Sellers WR, Sartor O. Amplification and overexpression of prosaposin in prostate cancer. Genes Chromosomes Cancer, 44(4): 351-64, 2005.
  • Sartor O, Reid R, Hoskin P, Quick D, Ell P, Coleman R, Kotler J, Freeman L, Olivier P. Samarium-153-lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology, 63:940-5, 2004.

Back to the top

Aline B. Scandurro Aline B. Scandurro, Ph.D.

Research Assistant Professor of Microbiology
TCC Program Member
alibscan@tulane.edu
(504) 988-1934, (504) 988-5144 fax
1601 Perdido Street, New Orleans, LA 70112
Homepage on the Microbiology website:

http://www.som.tulane.edu/departments/microbiology/scandurro.htm

Biographical information:

Dr. Scandurro received her B.S. in Biochemistry from Tulane University in 1985. She received her Ph.D. in 1992 in Microbiology from Georgetown University Medical Center and completed a postdoctoral fellowship in 1993 at the National Institutes of Health, Laboratory of Cellular Carcinogenesis and Tumor Promotion, National Cancer Institute. She completed a second fellowship in 1997 at the Tulane Cancer Center, Department of Pharmacology, Tulane University Medical Center, She joined the Tulane faculty in 1997 as a Research Instructor and became a Research Assistant Professor in 1999.


Dr. Scandurro's research focuses on oxygen-sensing genetic mechanisms, post-transcriptional control of oxygen-regulated genes, RNA binding proteins, angiogenesis and cancer research. Tumors require the formation of new blood vessels, angiogenesis, to grow. Targeting angiogenesis provides a novel approach for cancer therapy that rivals conventional therapy since drug resistance and tissue toxicity issues are avoided. Tumor angiogenesis depends on a balance between tumor-dependent angiogenic factors like VEGF (vascular endothelial growth factor) and host anti-angiogenic peptides like endostatin and angiostatin. The ability to alter this balance by favoring the anti-angiogenic effect by treatment with exogenous endostatin and angiostatin has been demonstrated. However, a major difficulty in translating these strategies to the clinic is the lack of large quantities of these peptides for long-term treatment. An alternative strategy to disturb this balance is to disrupt VEGF or other angiogenic factor production. EGF, like the hematopoietic growth factor erythropoietin (Epo), is usually synthesized following low oxygen or hypoxic stress. Since VEGF is a potent mitogen for vascular endothelial cells this response represents a means to quickly develop new blood vessels to bring oxygenated red blood cells and rescue the stressed tissue. Growing tumor cells become hypoxic and trigger or exploit this normal physiologic process. VEGF and Epo induction by hypoxia is largely controlled at the level of message stability. Post-transcriptional mechanisms have been implicated for VEGF and Epo since a physiologic drop in oxygen tension leads to induction of gene expression. However, increases in mRNA transcription does not exactly parallel the observed increased level of expression; thus it has been postulated that post-transcriptional stabilization of the normally labile VEGF and Epo mRNAs may account for the observed increased VEGF and Epo levels. Investigations in this laboratory have identified a complex of proteins, erythropoietin mRNA binding protein complex (ERBP30 and 70), in cytoplasmic lysates of human hepatocellular carcinoma (Hep3B) cells which specifically bind to a 120 nucleotide (nt) region in the 3' untranslated region (UTR) of Epo mRNA, VEGF mRNA as well as tyrosine hydroxylase (TH) mRNA. Additionally, a stabilizing role has been suggested for this region from studies in which deletion of this 120 nt region lead to an unchanged mRNA half-life in response to hypoxia (6 hrs) as compared to a forty percent increase in half-life observed for the wild-type mRNA. Production of VEGF and Epo is likely to be controlled post-transcriptionally by specific binding of the ERBP30 and ERBP70 complex to the 3' UTR of the VEGF and Epo mRNA. Current efforts are centered on understanding oxygen-sensing at the post-transcriptional level with the hypothesis that ERBP30 and ERBP70 are common post-transcriptional factors involved in oxygen-sensing.



Recent Publications:

Back to the top

Charles D. ScherCharles D. Scher, M.D.

Marcelle Shaeffer Vergara Chair Professor of Pediatrics
Chief of the Section of Pediatric Hematology-Oncology
TCC Associate Member
cscher@tulane.edu
(504) 988-5412, (504) 988-2557 fax
1430 Tulane Ave., Box SL-37, New Orleans, LA 70112-2699


Biographical information:

Dr. Scher received his B.A. in 1961 from Brandeis University and earned his medical degree in 1965 from the University of Pennsylvania. He served an internship and residency at Bronx Municipal Hospital/Albert Einstein College of Medicine in New York and a residency in pediatrics fellowship in pediatric hematology at Children's Hospital Medical Center, Harvard Medical School. He also served as a lieutenant commander from 1967-1971 in the United States Public Health Service at the National Cancer Institute in Bethesda, Maryland. After teaching and research fellowships in pediatrics at Harvard Medical School, Dr. Scher joined the Harvard faculty where he rose to the rank of associate professor of pediatrics. While at Harvard he was a visiting scientist in the Department of Biology at the Massachusetts Institute of Technology. Dr. Scher joined the University of Pennsylvania Medical School in 1982 as professor of pediatrics and human genetics. He joined the Tulane faculty in 1994. Dr. Scher specializes in pediatric hematology and oncology. He has served as bench researcher, mentor, and reviewer in investigations in acute lymphoblastic leukemia and the molecular biology of cancer. Dr. Scher is an accomplished basic scientist in the fields of the cellular and molecular biology of cancer, especially in the definition of the viruses causing leukemia, and the study of platelet derived growth factor, which has been implicated in the replication of normal connective tissue cells as in process of wound healing. He has served as principal investigator on six NIH-funded projects and one privately funded grant project, and has been responsible for extramural funding for numerous graduate students and junior faculty working in his laboratories. He is author of over 90 original publications and abstracts in his field.


Recent Publications:
  • Belasco JB, Luery N, Scher CD. (1990) Multiagent chemotherapy in relapsed acute lymphoblastic leukemia in children. Cancer 66: 2492-2497.
  • Meister L, Uri A, Agrons G, Scher CD. (1993) Wilms' tumor bone metastases at diagnosis. Med Ped Oncol 21: 446-450.
  • Kahn MJ, Scher CD, Rozans MR, Michaels RK, Leissinger C, Krause J. (1997) Factor V Leiden is not responsible for stroke in patients with sickling disorders and is uncommon in African Americans with sickle cell disease. Am J Hem 54: 12-15.
  • Adams RJ, McKie VC, Hsu L, Files B, Vichinsky E, Pegelow C, Abboud M, Gallagher D, Kutlar A, Nichols FT, Bonds DR, Brambilla D, Woods G, Olivieri N, Driscoll C, Miller S, Wintred W, Huriett A, Scher CD, Berman B, Carl E, Jones AM, Roach ES, Wright E, Zimmerman RA, Waclawiw M. (1998) Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial doppler ultrasonography. New Eng J Med 339: 5 - 11.
  • Leahey AM, Bunin NJ, Belasco JB, Meek R, Scher CD, Lange BJ. (2000) Novel multiagent chemotherapy for bone marrow relapse of pediatric acute lymphoblastic leukemia. Med Ped Oncol 34: 313-318.

Back to the top

Bin ShanBin Shan, M.D., Ph.D.

Assistant Professor of Medicine, Section of Pulmonary Medicine
TCC Program Member
bshan@tulane.edu
(504) 988-2343, (504) 988-2144 fax
1430 Tulane Ave., SL-9, New Orleans, LA 70112


Biographical information:

Dr. Shan received his M.D. at Hunan Medical University, P.R. China in 1994. He completed his Ph.D. training with Dr. Gilbert F. Morris in the Molecular and Cellular Biology Department at Tulane University in 2003. Dr. Shan carried out his postdoctoral research with Dr. Joseph A. Lasky in the Department of Medicine, Pulmonary Section at Tulane Medical School from 2003 - 2006. During his postdoctoral training, he made major contributions to the awards of two NIH RO1 grants to Dr. Lasky. He then joined the Pulmonary Section as an assistant professor in 2006. Dr. Shan's ongoing research focuses on lung tumorigenesis and viral mediators in lung diseases.

Recent Publications:

  • Shan B, Zhuo Y, Chin D, Morris CA, Morris GF, Lasky JA. CDK9 is required for tumor necrosis factor-alpha stimulated MMP-9 expression in human lung adenocarcinoma cells. J Biol Chem, 280(2): 1103-11, 2005.
  • Shan B, Xu J, Zhuo Y, Morris CA, Morris GF. Induction of p53-dependent activation of the human proliferating cell nuclear antigen gene in chromatin by ionizing radiation. J Biol Chem, 278(45): 44009-17, 2003.
  • Shan B, Morris GF. Binding sequence-dependent regulation of the human proliferating cell nuclear antigen promoter by p53. Exp Cell Res, 305(1): 10-22, 2005.
  • Shan B, Morris CA, Zhuo Y, Shelby BD, Levy DR, Lasky JA. Activation of proMMP-2 and Src by HHV8 vGPCR in human pulmonary arterial endothelial cells. J Mol Cell Cardiol, 42(3): 517-25, 2007.

 

Back to the top

Judd E.Shellito
Lowenstein Professor of Medicine
Professor of Microbiology, Immunology, and Parasitology

Positions and Employment:

  • 1974-1978 Internship/Residency, Internal Medicine, Northwestern University School of Medicine, Evanston Hospital, Evanston, Illinois
  • 1978-1980 Pulmonary Fellow, Department of Medicine, Pulmonary Division, University of New Mexico School of Medicine
  • 1980-1982 Research Fellow, Laboratory of H. Benfer Kaltreider, M.D., Cardiovascular Research Institute, University of California San Francisco
  • 1982-1989 Assistant Chief, Respiratory Care Section Director, Chest Clinic, Veterans Administration Medical Center, San Francisco, California
  • 1982-1989 Assistant Professor of Medicine in Residence, University of California San Francisco
  • 1988-1989 Member, Associate Staff, Cardiovascular Research Institute, University of California San Francisco
  • 1989-1990 Associate Professor of Medicine in Residence, University of California San Francisco
  • 1990-1993 Associate Professor of Medicine, LSU Medical Center, New Orleans, Louisiana
  • 1990-1993 Associate Professor of Microbiology, Immunology, and Parasitology, LSU Medical Center, New Orleans, Louisiana
  • 1990-1998 Director, Pulmonary/Critical Care Fellowship Program, LSU Medical Center, New Orleans, Louisiana
  • 1994-present Professor of Medicine, LSU Medical Center, New Orleans, Louisiana
  • 1994-present Professor of Microbiology, Immunology, and Parasitology, LSU Medical Center, New Orleans, Louisiana
  • 2003-2004 Acting Director, LSUHSC Gene Therapy Program, LSU Health Sciences Center, New Orleans, LA
  • 2007-present Acting Section Chief, LSUHSC Section of Pulmonary/Critical Care Medicine, LSU Health Sciences Center, New Orleans, LA

Selected Publications:

  • Shellito J, Suzara V, Blumenfeld W, Beck J, Steger H, Ermak T. A new model of Pneumocystis carinii infection in mice selectively depleted of helper T lymphocytes. J Clin Invest 1990;85:1686-1693.
  • Beck JM, Warnock ML, Curtis JL, Sniezek MJ, Arraj-Peffer SM, Kaltreider HB, Shellito J. Inflammatory responses to Pneumocystis carinii in mice selectively depleted of helper T lymphocytes. Am J Respir Cell Mol Biol 1991;5:186-197.
  • Beck JM, Liggitt HD, Brunette EN, Fuchs HJ, Shellito JE, Debs RJ. Reduction in intensity of Pneumocystis carinii pneumonia in mice by aerosol administration of interferon-gamma. Infection and Immunity 1991;59:3859-3862.
  • Nelson S, Bagby G, Andresen J, Nakamura C, Shellito J, Summer W. The effects of ethanol, tumor necrosis factor, and granulocyte colony-stimulating factor on lung antibacterial defenses. Adv Exp Med Biol 1991;288:245-253.
  • Beck J, Warnock M, Kaltreider HB, Shellito J. Host defenses against Pneumocystis carinii in mice selectively depleted of CD4+ lymphocytes. Chest 1993;103:116S-118S.
  • Kolls J, Beck J, Nelson S, Shellito J. Alveolar macrophage release of tumor necrosis factor during murine Pneumocystis carinii pneumonia. Amer J Respir Cell Mol Biol 1993;8:370-376.
  • Davis L, Beck JM, Shellito J. Update: human immunodeficiency virus infection and pulmonary host defenses. Seminars in Respir Infec 1993;8:1-11.
  • D’Souza NB, Mandujano F, Nelson S, Summer WR, Shellito JE. CD4+ T lymphocyte depletion attenuates LPS-induced TNF secretion by alveolar macrophages in the mouse. Lymphokine and Cytokine Research 1994;13:359-366.
  • Mandujano JF, D’Souza NB, Nelson S, Beckerman RC, Summer WR, Shellito JE. Reduction in intensity of Pneumocystis carinii pneumonia in mice by subcutaneous administration of granulocyte-macrophage colony stimulating factor. Amer J Resp Crit Care Med 1995;151:1233-1238.
  • D’Souza NB, Mandujano JF, Nelson S, Summer WR, Shellito JE. Alcohol ingestion impairs host defenses predisposing otherwise healthy mice to Pneumocystis carinii infection. Alcoholism: Clinical and Experimental Research 1995;19:1219-1225.
  • Kolls JK, Lei D, Odom G, Nelson S, Summer WR, Beutler B, Shellito JE. Transient CD4-lymphocyte depletion prolongs transgene expression of E1-deleted adenoviral vectors. Human Gene Therapy 1996;7:489-497.
  • Shellito JE, Kolls JK, Olariu R, Beck JM. Nitric oxide and host defense against Pneumocystis carinii infection in a mouse model. Journal of Infectious Diseases 1996;173:432-439.
  • Lei D, Lehmann M, Shellito JE, Nelson S, Siegling A, Volk HD, Kolls JK. Non-depleting anti-CD4 antibody treatment prolongs lung-directed E1-deleted adenovirus-mediated gene expression in rats. Human Gene Therapy 1996;7:2273-2279.
  • Kolls JK, Lei D, Odom G, Vazquez C, Summer WR, Nelson S, Shellito JE. Exacerbation of murine Pneumocystis carinii infection by adenoviral-mediated gene transfer of a TNF inhibitor. Am J RespirCell Mol Biol 1997;16:112-118.
  • Lei D, Lancaster J, Joshi M, Nelson S, Stoltz D, Bagby G, Odom G, Shellito JE, Kolls JK. Activation of alveolar macrophages and lung host defenses using transfer of the interferon-gamma gene. Am J Physiol 1997;272:L852-L859.
  • Lei C, Stoltz D, Zhang P, Schwartzenberger PO, Ye P, Nelson S, Bagby G, Summer WR, Shellito JE, Kolls JK. Adenoviral-mediated interferon-gamma gene therapy augments pulmonary host defense of acutely alcoholic rats. Alcoholism: Clinical and Experimental Research 1998;22:157-162.
  • Omidvari K, Casey R, Olariu R, Shellito JE. Alveolar macrophage release of tumor necrosis factor-alpha in chronic alcoholics without liver disease Alcoholism: Clinical and Experimental Research 1998;22:567-572.
  • Shellito JE, Olariu R. Alcohol decreases T lymphocyte migration into lung tissue in response to Pneumocystis carinii and depletes T lymphocyte numbers in the spleens of mice. Alcoholism: Clinical and Experimental Research 1998;22:658-663.
  • Prakash O, Zhang P, Xie M, Ali M, Zhou P, Coleman R, Shellito JE, Stoltz DA, Bagby GJ, Nelson S. The human immunodeficiency virus type I Tat protein potentiates ethanol-induced neutrophil function-impairment in transgenic mice. Alcoholism: Clinical and Experimental Research 1998;22:2043-2049.
  • Kolls JK, Vazquez C, Lei D, Schwarzenberger P, Ye P, Nelson S, Summer WR, Shellito JE. Interferon-gamma and CD8+ T-cells restore host defense against P. carinii in mice lacking CD4+ T-cells. J Immunology 1999;162:2890-2894.
  • Shean MK, Baskin G, Sullivan D, Shellito JE, Schwarzenberger PO, Kolls JK. Immunomodulation and adenoviral gene transfer to the lungs of non-human primates. Human Gene Therapy 2000:11:1047-1055.
  • Shellito JE, Tate C, Ruan S, Kolls J. Murine CD4+ T-lymphocyte subsets and host defense against Pneumocystis carinii. J Infec Dis 2000;181:2011-2017.
  • Prakash O, Rodriguez VE, Tang ZY, Zhou P, Coleman R, Shellito JE, Spitzer JJ, Nelson S. Inhibition of hematopoietic progenitor cell proliferation by ethanol in human immunodeficiency type 1 Tat-expressing transgenic mice. Alcoholism: Clin Exp Res 2001;25:450-456.
  • Ye P, Rodriquez FH, Kanaly S, Schurr J, Schwarzenberger P, Oliver P, Huang W, Zhang P, Shellito JE, Bagby GJ, Nelson S, Peschon JJ, Kolls JK. Requirement of IL-17 receptor signaling for lung CXC chemokine and G-CSF expression, neutrophil recruitment, and host defense. J Exp Med. 2001;194:519-527.
  • Kolls JK, Ye P, Shellito JE. Gene therapy to modify pulmonary host defenses. Sem in Respir Infections 2001;16:18-26.
  • Ye P, Garvey PB, Zhang P, Nelson S, Bagby G, Summer WR, Schwarzenberger P, Shellito JE, Kolls JK. IL-17 and lung host defense against K. pneumoniae infection. Am J Respir Cell Mol Biol. 2001;25:335-340.
  • Zheng M, Shellito J, Marrero L, Zhong Q, Julian S, Ye P, Wallace V, Schwarzenberger P, Kolls JK. CD4 T-cell independent vaccination against Pneumocystis carinii in mice. J Clin Invest 2001;108:1469-1474.
  • Mason CM, Dobard E, Shellito J, Nelson S. CD4+ lymphocyte responses to pulmonary infection with Mycobacterium tuberculosis in naïve and vaccinated BALB/c mice. Tuberculosis 2001;81:327-334.
  • Steele C, Zheng M, Young E, Marrero, Shellito JE, Kolls JK. Host Resistance Against Pneumocystis carinii Pneumonia in gamma delta T Cell-Deficient Mice: Protective Role of IFN- and CD8 T cells. Infection and Immunity 2002;70:5208-5215.
  • Happel KI, Zheng M, Quinton LJ, Lockhart E, Ramsay AJ, Shellito JE, Schurr JR, Bagby GJ, Nelson S, Kolls JK. Cutting Edge: Roles of Toll-Like Receptor 4 and IL-23 in IL-17 Expression in Response to Klebsiella pneumoniae Infection. J. Immunol 2003;170:4432-4436.
  • Ruan S, Tate C, Lee JJ, Ritter T, Kolls JK, Shellito JE. Local delivery of the viral IL-10 gene suppresses tissue inflammation in murine P. carinii infection. Infection and Immunity 2002;70:6107-6113.
  • Steele C, Shellito JE, Kolls JK. Macrophage-mediated killing mechanisms against Pneumocystis carinii. J. Exp Med.2003;198:1677-1688.
  • Shellito JE. Failure of Host Defenses in HIV. In: Nelson S, Standiford T, Issue Editors, Pulmonary Defense Mechanisms in Infection. Seminars in Respiratory and Critical Care Medicine 2004;35:73-84.
  • McAllister F, Steele C, Zheng M, Young Erana, Shellito JE, Marrero L, Kolls JK. Tc1 CD8+ T-cells are effector cells against Pneumocystis in mice. J Immunol 2004;172:1132-1138.
  • Schurr JR, Young E, Byrne P, Steele C, Happel K, Shellito JE, Kolls JK. Central role of TLR4 signaling and host defense in experimental gram negative pneumonia. Infection and Immunity 2005;73:532-545.
  • Badewa AP, Quinton LJ, Shellito JE, Mason CM. Chemokine receptor 5 and its ligands in the immune response to murine tuberculosis. Tuberculosis. 2005;85:185-195.
  • Happel KI, Dubin PJ, Zheng M, Ghilardi N, Lockhart C, Quinton LJ, Odden AR, Shellito JE, Bagby GJ, Nelson S, Kolls JK. Divergent roles of IL-23 and IL-12 in host defense gainst Klebsiella Pneumoniae. J Exp Med 2005;202:761-769.
  • Ruan S, Young E, Luce MJ, Reiser J, Kolls JK, Shellito JE. Conditional expression of interferon-gamma to enhance host responses to pulmonary bacterial infection. Pulmonary Pharmacology and Therapeutics. 2005;19:251-257.
  • Steele C, Shellito JE, Kolls JK. Immunity against the opportunistic fungal pathogen Pneumocystis. Medical Mycology 2004;43:1-19.
  • Zheng M, Ramsay A, Robichaux M, Norrise KA, Kliment C, Crowe C, Steele C, McAllister F, Shellito JE, Marrero L, Zhong Q, Kolls JK. CD4+ T-cell independent DNA vaccination against Pneumocystis carinii in mice. J. Clin. Invest 2005;115:3536 – 3544.
  • McAllister F, Ruan S, Kolls JK, Shellito JE. CXCR3 and IP-10 Pneumocystis pneumonia. J Immunology 2006;177:1846-1854.
  • McAllister F, Steele C, Zheng M, Shellito JE, Kolls JK. In vitro effector activity of Pneumocystis-specific T cytotoxic-1 CD8+ T-cells: role of GM-CSF. Infec Immun 2005;73:7450-7457.
  • Rudner XL, Happel KI, Young EA, Shellito JE. The IL-23/IL-17 cytokine axis in murine Pneumocystis infection. Infection and Immunity 2007;75:3055-3061.
  • Ruan S, McKinely L, Zheng M, Rudner X, Kolls J, Shellito JE. Interleukin-12 and host defense against murine Pneumocystis pneumonia. In press, Infection and Immunity.

 

Back to the top

Maureen ShuhMaureen Shuh, Ph.D.

Associate Professor, Division of Basic Pharmaceutical Sciences, College of Pharmacy
TCC Associate Member
mshuh@xula.edu
(504) 520-7523, (504) 520-7954 fax
Xavier University of Louisiana, 1 Drexel Drive, New Orleans, LA 70125


Biographical information:

Dr. Shuh obtained her B.A. in microbiology and immunology at the University of California at Berkeley. While at Berkeley, she worked in the laboratory with Dr. Hitoshi Sakano's graduate student Thomas Hope (now at Northwestern University). After graduation, Dr. Shuh worked for Dr. Kathelyn Steimer at Chiron Corporation on an HIV vaccine project. Working with Hope and Steimer led her to pursue a Ph.D., which she completed at Brown University in 1996 under the direction of Dr. Douglas Hixson, who is the director of the COBRE Center for Cancer Research Development at Rhode Island Hospital. After obtaining her Ph.D., she pursued a postdoctoral fellowship with Dr. David Derse at the National Cancer Institute (NCI). She continues her close collaboration with Derse on SRF-TAX.

Recent Publications:

  • Shuh M, Beilke M. The human T-cell leukemia virus type I (HTLV-I): new insights into the clinical aspects and molecular pathogenesis of adult T-cell leukemia/lymphoma (ATLL) and tropical spastic paraparesis/HTLV-associated myelopathy (TSP/HAM). Microscopy Research and Technique (special issue on virus and neoplasia), 68:176-196, 2005.
  • Streich FC, Pryor KN, Thomassie LM, Shuh M. Identification of Tax regions of protein interaction with ternary complex factor (TCF) and SRF. AIDS Research and Human Retroviruses, 21: 495, 2005.
  • Shuh M, Hixson DC. V(D)J recombination of chromosomally integrated, wild-type deletional and inversional substrates occurs at similar frequencies with no preference for orientation. Immunology Letters, 97(1): 69-80, 2005.
  • Shuh M, Derse D. Ternary complex factors and cofactors are essential for human T-cell leukemia virus type I Tax transactivation of the serum response element. Journal of Virology, 74(23): 11394-11397, 2000.
  • Derse D, Shuh M, Hill SA. Examining HTLV-I gene function and expression with molecularly closed proviruses. In Molecular Pathogenesis of HTLV-I: A Current Prospective. Arlington, Virginia: ABI Professional Publications.
  • Hill SA, Shuh M, Derse D. Comparisons of defective HTLV-I proviruses predict the mode of origin and coding potential of internally deleted genomes. Virology, 263: 273-281, 1999.
  • Shuh M, Hill SA, Derse D. Defective and wild-type HTLV-I proviruses: characterization of gene products and potential trans-interactions between proviruses. Virology, 262: 442-451, 1999.

Back to the top

Suresh C. Sikka Suresh C. Sikka, Ph.D., HCLD

Associate Professor of Urology
Adjunct Associate Professor of Pharmacology and Biochemistry
Director of Andrology Clinic and Research Laboratories
TCC Associate Member
ssikka@tulane.edu
(504) 988-5179, (504) 988-5059 fax
1430 Tulane Ave., Box SL-42, New Orleans, LA 70112-2699
Homepage on the Urology website:
http://www.som.tulane.edu/departments/urology/faculty/sikka.html


Biographical information:

Dr. Sikka received his Ph.D. from the Department of Pharmacology, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India, in 1978. He did his post-doctoral fellowship from 1979-1982 in the Department of Biochemistry at the University of Southern California (USC), Los Angeles where he obtained training in the field of protein-lipid interactions in cell membranes, protein purification, and functional incorporation into liposomes. In 1982 Dr. Sikka moved to the Urology section of the Department of Surgery at Harbor-UCLA Medical Center, University of California Los Angeles (UCLA), as Urology Laboratory Research Director. Dr. Sikka joined the Tulane faculty in 1989 as Assistant Professor of Urology and Andrology Laboratory Director. He was responsible for setting up a CLIA-approved Andrology Clinical and Research Laboratory at Tulane Medical Center, catering to the needs of many infertility and sexual dysfunction patients. Dr. Sikka's current research focus is oxidative stress-related signal transduction pathways and gene expression involved in prostate tumorigenesis (BPH and cancer) and drug targeting. The Urology department has recently procured a Laser Capture Microscope (LCM) to microdissect specific and selective biological cells from various clinical samples. LEQSF has also recently funded the Department to acquire the latest DNA - microarray system for expression of specific genes (genomics), and their translational products (proteonomics). The lab routinely employs molecular biology, differential gene expression, suppressive subtractive hybridization, other cell biology, biochemical, and chemiluminescence techniques as well as xenograft and transgenic models of disease and in situ studies on human tissues approaches to address many questions as they relate to prostate tumorigenesis. Using a super-repressor I kappa B adenoviral delivery approach, the lab plans to evaluate the role of inhibiting the activation of the nuclear factor NF-kappa B in enhancing radio/chemosensitization and apoptosis of prostate tumor cells. Analysis of the expression and function of these genes should allow for a more in depth understanding of the processes controlling prostate tumor growth, invasion and metastasis. The ultimate aim is on developing new diagnostic tools and potential therapeutic applications using a gene therapy approach (pharmacogenomics).



Recent Publications:
  • Sikka SC. (2001) Relative Impact of Oxidative Stress on Male Reproductive Function. Current Medicinal Chem 1: 851-862.
  • Rajasekaran M, Hellstrom WJG, Sikka SC. (2001) Nitric oxide induces oxidative stress and mediates cytotoxicity to human cavernosal cells in culture. J Androl 22: 34-39.
  • Sikka SC, Champion H, Bivalacqua TJ, Estrada L, Wang R, Rajasekaran M, Aggarwal B, Hellstrom WJG. (2001) Role of genitourinary inflammation of infertility: detrimental effect of lipopolysaccharide (LPS) and nterferon-gamma on human spermatozoa. Int J Androl (in press).
  • Nguyen A, Jing S, Mahoney S, Davis R, Sikka SC, Agrawal KC, Abdel-Mageed AB. (2000) In vivo gene expression profile analysis of metallothionein in renal cell carcinoma. Cancer Letters 160: 133-140.
  • Bivalacqua TJ, Champion HC, Mehta YS, Abdel-Mageed AB, Sikka SC, Ignarro LJ, Kadowitz PJ, Hellstrom WJG. (2000) Adenoviral gene transfer of endothelial nitric oxide synthase (eNOS) to the penis improves age-related erectile dysfunction in the rat. Int J Impotence Res 12: 8-17.
  • Armstrong JS, Rajasekaran M, Chamulitrat W, Gatti P, Hellstrom WJG, Sikka SC. (1999) Characterization of reactive oxygen species induced effects on human spermatozoa movement and energy metabolism. Free Radical Biol Med 26(7/8): 869-80.

Back to the top

Sudesh K. Srivastav Sudesh K. Srivastav, Ph.D.

Assistant Professor of Biostatistics, Tulane School of Public Health and Tropical Medicine
TCC Contributing Member
ssrivas@tulane.edu
(504) 988-2472, (504) 988-1706 fax
1430 Tulane Ave., Box SL-16, New Orleans, LA 70112-2699
Homepage on the Biostatistics website:
http://www.biostatistics.tulane.edu/bio_pages/faculty_bio/srivatav.html


Biographical information:

Dr. Srivastav received his masters degree in Statistics from Indian Statistical Institute in 1988 and another masters degree in Applied Mathematics from New Jersey Institute of Technology, New Jersey in 1990. He received his Ph.D. in Design of Experiments from Old Dominion University, Virginia in 1996 and in the same year he took a faculty position at University of California at San Francisco as Assistant Adjunct Professor in Biostatistics. In 1999 he joined the Department of Biostatistics at Tulane's School of Public Health and Tropical Medicine. He became an honorary fellow at the Center of Mathematical Sciences at the University of Wisconsin, Madison in summer 2000. Dr. Srivastav will be a research fellow at the Department of Statistics at Stanford University during summer 2001. Dr. Srivastav has published numerous papers in both theoretical and applied statistical and medical journals. His research is focussed on methodology that is devoted toward establishing the optimality and construction of block designs under a different set of parameters (number of treatments, number of blocks and block size, etc). This research will provide a simple classification scheme of study designs that can be useful in the field of health science, agricultural science and industrial engineering.



Recent Publications:
  • Morgan JP, Srivastav SK. (2000) On the Type-1 optimality of Nearly Balanced Incomplete Block Designs with small Concurrence range. Statistica Sinica 10(4): 1091-1116.
  • Bonel HM, Schneider P, Seemann MD, Hugli R, Srivastav SK, Lodemann KP, Reiser M. (2001) MR imaging of the wrist in rheumatoid arthritis using gadobenate dimeglumine. Skel Radiol 30: 15-24.
  • Prevrhal S, Fuerst T, Fan B, Njeh CF, Hans D, Uffmann M, Srivastav SK, Genant HK. (2001) What Does Quantitative Ultrasound of the Tibia Measure? Osteop Int 12(1): 20-26.
  • Hans D, Srivastav SK, Njeh CF, Singal C, Wu C, Genant HK. (1999) Does combining the results from multiple bone sites measured by a new Quantitative Ultrasound improve discrimination of hip fracture? J Bone Min Res 14(4): 644-651.

Back to the top

Joy ESturtevant
Associate Professor

Positions and Employment:

  • 1991-1992 Visiting Scientist, University of Pierre and Marie Curie, Paris France
  • 1994-2000 Assistant Professor on Research Track, Department of Microbiology, Georgetown University Medical School, Washington DC
  • 2000-2002 Associate Professor on Resarch Track, Department of Microbiology, Georgetown University Medical School, Washington DC
  • 2002 - 2005  Assistant Professor, Department of Microbiology, Center of Excellence for Oral and Craniofacial Biology Louisiana State University Health Sciences Center, New Orleans, LA
  • 2002 - 2005 Assistant Professor, -joint appt. Department of Periodontics, Louisiana State University  School of Dentistry.
  • 2005 - Associate Professor, Department of Microbiology, Immunology and Parasitology Louisiana State University Health Sciences Center, New Orleans, LA
  • 2005 - Associate Professor, -joint appt. Department of Oral Biology Louisiana State University  School of Dentistry
Selected Publications:
  • Sturtevant, J.E. & J-P. Latgé. 1992. Participation of complement in the phagocytosis of the conidia of Aspergillus fumigatus by human PMN. J Infect Dis, 166:580-586.
  • Sturtevant, J.E. & J-P. Latgé. 1992. Interactions between the conidia of Aspergillus fumigatus and human complement component C3. Infect Immun, 60:1913-1918.
  • DeBernardis, F., A. Cassone, J. Sturtevant, & R. Calderone. 1995. Expression of secreted aspartyl proteinases SAP-1 and SAP-2 in experimental vaginitis caused by Candida albicans. Infect Immun. 63:1887-1892.
  • Sturtevant, J.E., Cihlar, R.L., and R.A. Calderone. 1998. Disruption studies of a Candida albicans gene, ELF1, A member of the ATP binding cassette family. Microbiol. 144: 2311-2321.
  • Sturtevant, J., F. Dixon, Wadsworth, E., J.-P. Latgé, X-J. Zhao, and R. Calderone.1999. Identification and cloning of GCA1, a gene which encodes a cell wall glucoamylase from Candida albicans. Med Myc. 37:357-366.
  • Sturtevant, J.E. 2000. Differential display reverse transcriptase PCR (DDRT-PCR): Its application to molecular pathogenesis and medical mycology. Clinical Reviews in Microbiology 13:408-427.
  • Cognetti, D., Davis, D., and J. Sturtevant. 2002. The Candida albicans 14-3-3 gene, BMH1, is essential for growth. Yeast, 19:55-67.
  • Sturtevant, J. 2002. Elongation factors: are they rational antifungal targets? Emerging Therapeutic Targets. Expert Opinion on Therapeutic Targets,6:545-553.
  • Palmer, G., Cashmore, A. and J. Sturtevant. 2003. Germtube formation in Candida albicans is dependent on vacuole function. Eukaryotic Cell,2:411-421.
  • Sturtevant, J. & Cihlar, R.L. 2003. Strategies for the Study of Gene Expression in Fungi. In The Mycota Vol XII: Human Fungal Pathogens, J.E. Domer & G.S. Kobayashi, eds. Springer-Verlag, Heidelberg Germany.
  • Palmer, G., Cashmore, A. and J. Sturtevant. 2003. Germtube formation in Candida albicans is     dependent on vacuole function. Eukaryotic Cell,2:411-421.
  • Fidel, P.L., Jr., M.M. Barousse, T. Espinosa, M. Ficarra, J. Sturtevant, D.H. Martin, A.J. Quayle, K. Dunlap. 2004. New insights into the immunopathogenesis of vaginal candidiasis through a live Candida challenge in humans. Infect. Immun. 72:2939-2946.
  • Palmer, G.E, Johnson, K.J., Ghosh, S and Sturtevant, J. 2004.Mutant alleles of the essential 14-3-3 gene in Candida albicans distinguish between growth and filamentation. Microbiology, 150:1911-1924.
  • Sturtevant, J.  2004. Meeting Report: Candida and Candidiasis. Mycopathologia, 158: 141-146.
    Palmer, G.E. and Sturtevant, J.  2004. Random mutagenesis of an essential C. albicans gene. Genetics 46: 343-356.
  • Palmer, G.E., Kelly, M. N., and J.E. Sturtevant. 2005. The Candida albicans vacuole is required for differentiation and efficient macrophage killing. Eukaryotic Cell, 4: 1677 - 1686.
  • Palmer, G.E., Kelly, M.N., and J.E. Sturtevant. 2007.Autophagy in the pathogen Candida albicans.Microbiology, 153: 51-8
  • Sturtevant, J. 2009. Reporter Gene Assays. In Candida albicans  Methods and Protocols, Springer Protocols: Methods in Molecular Medicine, R.A. Calderone & R.L. Cihlar, eds. P 157-168.
  • Kelly, M.N., Johnston, D.A., Peel, B.A., Morgan, T.W., Palmer, G.E., and J.E. Sturtevant. 2009. Bmh1p (14-3-3) mediates pathways associated with virulence in Candida albicans. Microbiology, 155: 1536-46.
  • Douglas A. Johnston, Karen E. Eberle, Joy E. Sturtevant, and Glen E. Palmer 2009. A role for endosomal and vacuolar GTPases in Candida albicans pathogenesis. Infection and Immunity. In press.

 

Back to the top

Deborah E. SullivanDeborah E. Sullivan, Ph.D.

Research Assistant Professor of Microbiology & Immunology
TCC Program Member
dsulliva@tulane.edu
1430 Tulane Ave., Box SL-38, New Orleans, LA 70112-2699


 

 

Biographical information:

Dr. Sullivan received her B.S. (1984) and M.S. (1988) degrees in biology/microbiology from Southeastern Louisiana University. She earned her Ph.D. in molecular and cellular biology from Tulane University Health Sciences Center in 1999 and completed a postdoctoral fellowship at Louisiana State University Health Sciences Center, studying the role of HIV Tat-induced angiogenesis in the development of Kaposi's sarcoma in 2001. Dr. Sullivan joined the faculty of Tulane University Health Sciences Center as a research assistant professor in the Department of Microbiology and Immunology in 2001. Her research is focused on the molecular mechanisms involved in the development of pulmonary fibrosis and lung cancer in response to inhaled environmental agents. She is also interested in the use of stem cells as cell therapy to aid in the repair of injured lung and as vehicles to deliver therapeutic genes for the treatment of lung cancer.


Recent Publications:

  • Sullivan DE, Dash S, Due H, Hiramatsu N, Aydin F, Kolls J, Blanchard J, Baskin G, Gerber MA. Liver directed gene transfer in non-human primates. Hum Gene Ther, 8:1195-1206, 1997.
  • Shean MK, Baskin G, Sullivan DE, Cavender D, Shellito JE, Schwarzenberger PO, Kolls JK. Immunomodulation and adenoviral gene transfer to the lungs of non-human primates. Hum Gene Ther, 11:1047, 2000.
  • Morris CB, Thanawastein A, Sullivan DE, Clements JD. Identification of a peptide capable of inducing an HIV-1 Tat-specific CTL response. Vaccine, 20:12, 2002.
  • Sullivan DE, Mondelli M, Curiel D, Krasnykh V, Mikheeva G, Gaglio P, Morris C, Dash S, Gerber MA. Construction and characterization of an intracellular single-chain human antibody to hepatitis C virus nonstructural 3 protein. J. Hepatol, 37:660, 2002.
  • Sullivan DE, Ferris MB, Pociask D, Brody AR. TNF-alpha induces TGF-beta1 expression in lung fibroblasts through the ERK pathway. Am J Respir Cell Mol Biol, 32(4): 342, 2005.

Back to the top

Karen A. SullivanKaren A. Sullivan, Ph.D.

Research Professor of Medicine
Director of Histocompatability and Immunogenetics
TCC Associate Member
karens@tulane.edu
(504) 988-5259, (504) 988-3636 fax
1430 Tulane Ave., Box SL-75, New Orleans, LA 70112-2699

 


Biographical information:

Dr. Sullivan received her B.S. in 1966 from the Massachusetts College of Liberal Arts and her Ph.D. in 1973 from Duke University. She completed her postdoctoral research from 1973-1975 at the McIndoe Memorial Research Unit, Blond Laboratories, Queen Victoria Hospital, Sussex, England and was a postdoctoral fellow from 1975-1978 in the Division of Laboratories and Research, New York State Department of Health. Dr. Sullivan's Histocompatibility and Immunogenetics Laboratory provides histocompatibility testing support for the Tulane Multi-Organ Transplant programs which include kidney, liver, heart and pancreas. The laboratory also provides allogenic and autologous bone marrow transplantation. This support includes typing for the genes and antigens of the Major Histocompatability Complex (HLA) in order to determine the level of phenotypic and/or genetic HLA identity between individuals. It also includes crossmatching between recipient sera and donor lymphocytes; antibody screening of patient sera to determine the level of sensitization and specificity of antibodies to HLA antigens in the general population. The Histocompatability and Immunogenetics Laboratory also performs immunophenotyping of lymphocyte subsets. The laboratory also provides HLA typing for disease association and other non-transplant relateed reasons, including research. The laboratory has extensive expertise in HLA typing for Class I and Class II antigens by serological and molecular methodology, two- and three-color flow cytometry for immunophenotyping, antibody screening and crossmatching, enzyme-linked immunosobant assays for the detection and identification of antibodies specific for HLA antigens, isolation and viable freezing of PBMC and in vitro tissue culture, lymphoproliferative assays to mitogens and recall antigens, mixed lymphocyte culture assays and cell-mediate cytotoxic assyas for CTL and NK cell activity.



Recent Publications:

  • Jaspan JB, Breyer-Ash M, Sullivan KA, Lopez ML, Wolfe MA, Clejan S, Yan C, Ahmed B, Garry RF. (1996) The interaction of type-A retroviral particle and class II HLA susceptibility gees in the pathgenesis of Graves' disease. J Clin Endo Metab 81: 2271-2279.
  • Sullivan KA, Wolfe MA, Lopez M, Jaspan JJ, Breyer-Ash M. (1997) First report of recombination between the HLA-DR and HLA-DQ loci within a family. Hum Immunol 57: 37-43.
  • Sullivan KA, Kipps TS. (2000) "Human leukocyte and platelet antigens". In Williams' Hematology, 6th Edition. Beutler, Lichtman, Coller, Kipps and Seligsohn, Eds. McGraw-Hill.
  • Sullivan KA. (2000) "HLA and transplantation". In Molecular Tying 2000: A Technical Manual for Histocompatibility Laboratories. C.H. Manning, B. Burgess and F.E. Ward, Eds. Southeastern Organ Procurement Foundation.
  • Madan AK, Slakey DP, Becker A, Gill JI, Heneghan JL, Sullivan KA, Cheng S. (2000) Treatment of Antibody-mediated accelerated rejection using plasmapheresis. J Clin Apher 15: 180-183.

Back to the top

Li-Chun SunLi-Chun Sun , Ph.D.

Research Associate Professor of Medicine, Peptide Research
TCC Associate Member
lsun@tulane.edu
(504) 988-1179, (504) 988-3586 fax
1430 Tulane Ave., Box SL-12, New Orleans, LA 70112-2699

 

 

Biographical information:

Dr. Sun received his B.S. (1987) and M.S. (1990) from Xiamen University and earned his Ph.D. (1999) from Fudan University, P.R. China. In the same year, he joined the faculty of Tulane University Health Sciences Center as a research instructor in the Department of Medicine, Peptide Research Section, chaired by Dr. David H. Coy. Dr. Sun was promoted to research assistant professor in 2003 and research associate professor in 2007. In Dr. Coy's peptide research group, Dr. Sun established and is in charge of the biological branch of the laboratories. Dr. Sun's current research focuses on the development of peptide-based drugs and drug delivery systems in cancer therapeutics and their relevant mechanisms.

Recent Publications:

  • Sun LC, Luo J, Mackey LV, Fuselier JA, Coy DH. Effects of camptothecin on tumor cell proliferation and angiogenesis when coupled to a bombesin analog used as a targeted delivery vector. Anti-Cancer Drugs, 18(3): 341-8, 2007.
  • Sun LC, Luo J, Mackey LV, Fuselier JA, Coy DH. A conjugate of camptothecin and a somatostatin analog against prostate cancer cell invasion via a possible signaling pathway involving PI3K/Akt, alphaVbeta3/alphaVbeta5 and MMP-2/-9. Cancer Letters, 246(1-2): 157-66, 2007.
  • Moody TW, Sun LC, Mantey SA, Pradhan T, Coy DH, Jensen RT, et al. In vitro and in vivo anti-tumor effects of cytotoxic camptothecin-bombesin conjugates are mediated by specific interaction with cellular bombesin receptors. J Pharmacol Exp Ther, 318(3): 1265-1272, 2006.
  • Sun LC, Fuselier JA, Coy DH, et al. Effects of camptothecin conjugated to a somatostatin analog vector on growth of tumor cell lines in culture and related tumors in rodents. Drug Delivery, 11(4): 231-238, 2004.
  • Sun LC, Vasilevich NI, Coy DH, et al. Abilities of 3,4-diarylfuran-2-one analogues of combretastatin A-4 to inhibit proliferation of tumor cell lines and growth of the relevant tumors in nude mice. Anticancer Research, 24(1): 179-186, 2004.
  • Sun LC, Vasilevich NI, Coy DH, et al. Examination of the 1,4-disubstituted azetidinone ring system as a template for combretastatin A-4 conformationally restricted analogue design. Bioorg & Med Chem Lett, 14(9): 2041-2046, 2004.
  • Fuselier JA, Sun LC, Woltering SN, Murphy WA, Vasilevich NI, Coy DH. An adjustable release rate linking strategy for cytotoxin-peptide conjugates. Bioorg & Med Chem Lett, 13(5): 799-803, 2003.
  • Sun LC, Fuselier JA, Coy DH, et al. Antisense peptide nucleic acids conjugated to somatostatin analogs and targeted at the n-myc oncogene display enhanced cytotoxicity to human neuroblastoma IMR32 cells expressing somatostatin receptors. Peptides, 23(9): 1557-1565, 2002.
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Back to the top

 

Our Partners

Information for Researchers
 
more info »
 

Latest News
 
more news »